首页> 美国卫生研究院文献>other >Voriconazole-Induced Phototoxicity Masquerading as Chronic Graft-versus-Host Disease of the Skin in Allogeneic Hematopoietic Cell Transplant Recipients
【2h】

Voriconazole-Induced Phototoxicity Masquerading as Chronic Graft-versus-Host Disease of the Skin in Allogeneic Hematopoietic Cell Transplant Recipients

机译:伏立康唑诱导的光毒性伪装成异基因造血细胞移植受体皮肤的慢性移植物抗宿主病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Systemic fungal infections pose a significant risk to patients following allogeneic hematopoietic cell transplantation (alloHCT). Voriconazole (Vfend®, Pfizer) is an oral second-generation triazole antifungal agent that offers broad spectrum of coverage against fungal species and is frequently utilized in the post-HCT setting. Herein, we describe five patients who were initially believed to be experiencing a flare of cutaneous chronic graft-versus-host disease (cGvHD), but who were actually exhibiting phototoxicity caused by voriconazole. A high index of suspicion for this adverse reaction in the post-alloHCT setting will prevent misdiagnosis and avoid inappropriate therapy for cGvHD.
机译:异基因造血细胞移植(alloHCT)后,全身性真菌感染对患者构成了重大风险。伏立康唑(Vfend ®,辉瑞公司)是口服的第二代三唑类抗真菌药,对真菌种类具有广泛的覆盖范围,经常在HCT后使用。本文中,我们描述了五名患者,这些患者最初被认为患有皮肤慢性移植物抗宿主病(cGvHD)发作,但实际上表现出伏立康唑引起的光毒性。在alloHCT后的环境中高度怀疑这种不良反应将防止误诊并避免对cGvHD进行不适当的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号